PROTAGONIST THERAPEUTICS INC's ticker is PTGX and the CUSIP is 74366E102. A total of 137 filers reported holding PROTAGONIST THERAPEUTICS INC in Q2 2022. The put-call ratio across all filers is 0.19 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $932,175 | -69.6% | 33,750 | -74.7% | 0.35% | -63.0% |
| Q1 2023 | $3,069,396 | +41.0% | 133,452 | -33.1% | 0.94% | +6.1% |
| Q4 2022 | $2,177,000 | +29.4% | 199,500 | 0.0% | 0.88% | +90.7% |
| Q3 2022 | $1,682,000 | +37.2% | 199,500 | +28.7% | 0.46% | -8.0% |
| Q2 2022 | $1,226,000 | -93.3% | 155,000 | -79.9% | 0.50% | -92.9% |
| Q1 2022 | $18,216,000 | +69.7% | 769,250 | +145.0% | 7.12% | +68.3% |
| Q4 2021 | $10,736,000 | -30.0% | 313,929 | -8.1% | 4.23% | -15.8% |
| Q2 2021 | $15,333,000 | +130.3% | 341,650 | +32.9% | 5.02% | +203.9% |
| Q1 2021 | $6,659,000 | +27.4% | 257,086 | -0.8% | 1.65% | -13.0% |
| Q4 2020 | $5,227,000 | – | 259,283 | – | 1.90% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| JOHNSON & JOHNSON | 2,449,183 | $19,373,000 | 4.95% |
| Bain Capital Life Sciences Investors, LLC | 2,260,572 | $17,881,000 | 2.10% |
| Finepoint Capital LP | 735,126 | $5,815,000 | 2.01% |
| Altium Capital Management LP | 365,100 | $2,888,000 | 1.16% |
| RTW INVESTMENTS, LP | 4,794,499 | $37,924,000 | 0.98% |
| Amitell Capital Pte Ltd | 50,129 | $397,000 | 0.90% |
| COWEN AND COMPANY, LLC | 1,065,724 | $8,430,000 | 0.81% |
| Tri Locum Partners LP | 155,000 | $1,226,000 | 0.50% |
| BVF INC/IL | 1,106,838 | $8,755,000 | 0.42% |
| HighVista Strategies LLC | 46,459 | $367,000 | 0.22% |